Radiopraxis 2023; 16(04): 159-167
DOI: 10.1055/a-1954-5999

Innovative intravaskuläre Tumortherapie mittels Holmium-166

Innovative Intravascular Radioembolization Using 166Ho Microspheres
Tobias Oblasser
Nataliya Schubert
Frederic Koszarski

In der Welt der selektiven internen Radiotherapie (kurz: SIRT) dominierte bisher das Isotop Yttrium-90 (90Y). Seit 2015 ist mit Holmium-166 (166Ho) eine Alternative erhältlich, welches sich in unserem Institut neben 90Y etabliert hat. In diesem Artikel werden wir die Vor- und Nachteile der beiden Isotope beleuchten und einen klinischen Fall aus der Perspektive der Nuklearmedizin näher beschreiben.


The selective internal radiotherapy (SIRT) is a minimally invasive procedure to treat hepatic malignancies. For a long time, the isotope 90Y has been the primary choice for radioembolization. Beginning in 2015, 166Ho microspheres have become available and can be used for diagnostic and therapeutic purposes. They are ready-to-use products with short preparation and handling times. Most of the preparations, such as connecting the tubes and flushing them with saline, are done without the nuclide present. With specialized dosimetry software, estimation of the mean absorbed dose of lung, healthy liver, and tumor tissue is possible, making it feasible to plan more treatment sessions if necessary. The 166Ho microspheres have excellent physical characteristics for use with SPECT, such as a primary gamma peak of 81 keV. Due to the paramagnetic properties of 166Ho and the stable daughter nuclide 166Er, MRI imaging is also possible. The spheres are made of PLLA with a diameter of 15–60 µm. 166Ho has a half-life of 26,8 h, requiring the injection of a higher activity compared to 90Y. Apart from a short stay at the day clinic, it is possible to perform the therapy on an outpatient basis.

Publication History

Article published online:
28 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany